Company invites individual and institutional investors, as well as advisors to attend this interactive, real-time virtual investor conference
SUNNYVALE, Calif., Nov. 24, 2014 /PRNewswire/ -- Viveve Medical, Inc. (OTC QB: VIVMF) ("Viveve"), the parent company to Viveve, Inc., a company focused on women's health, today announced that Patricia Scheller, Viveve's Chief Executive Officer and Scott Durbin, Viveve's Chief Financial Officer will present live at VirtualInvestorConferences.com on December 4, 2014.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
Recent Company Highlights
- Became publicly traded under the symbol VIVMF following the completion of the merger of Viveve, Inc. and PLC Systems, Inc.
- Successfully raised $6 million in equity capital, including the conversion of $1.5 million in outstanding debt, to support additional clinical and global commercialization efforts
- Secured a $5 million term loan (of which Viveve, Inc. has drawn $2.5 million) to fund working capital, as we begin to more aggressively pursue sales of the Viveve System
- Preparing for the imminent launch of the VIVEVE I clinical trial in Europe and Canada
Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten the tissues of the vaginal introitus (opening) and requires only a 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.
Viveve is a registered trademark of Viveve, Inc.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire have been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Viveve Medical, Inc.